As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.

Eli Lilly on Thursday released late-stage data showing a 38% reduction in the risk of heart failure outcomes, as it plays ...

Sarepta has been hit with another patent infringement lawsuit, this time from Sanofi and its subsidiary Genzyme alleging that ...

Generative AI could enhance and accelerate the way people work on clinical trials. In this Q&A, a management consultant ...

Moderna’s stock price plunged more than 20% in Thursday morning trading after the company lowered its 2024 revenue guidance ...

Companies will look at job candidates’ LinkedIn profiles, so make sure yours is strong, from the summary of your expertise ...

Eisai presented a plethora of data on the drug at the Alzheimer’s Association International Conference, including a study ...

Within seven days of a death, “ (clinical trial) investigators usually are required to report any death or [severe adverse ...

As July comes to a close, biopharma second-quarter earnings continue to roll in with Pfizer, Merck, AbbVie, AstraZeneca and ...

Second-quarter revenues were better than analysts expected as Merck reported 16% growth for its blockbuster cancer treatment ...

Back-to-back failures in psoriasis and Crohn’s disease have forced Ventyx Biosciences to abandon the development of its ...

BioNTech and Regeneron will face off against Merck and Moderna, which are advancing their investigational cancer vaccine mRNA ...